264 related articles for article (PubMed ID: 12592338)
1. Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) up-regulation.
Bortul R; Tazzari PL; Cappellini A; Tabellini G; Billi AM; Bareggi R; Manzoli L; Cocco L; Martelli AM
Leukemia; 2003 Feb; 17(2):379-89. PubMed ID: 12592338
[TBL] [Abstract][Full Text] [Related]
2. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer.
Chen X; Thakkar H; Tyan F; Gim S; Robinson H; Lee C; Pandey SK; Nwokorie C; Onwudiwe N; Srivastava RK
Oncogene; 2001 Sep; 20(42):6073-83. PubMed ID: 11593415
[TBL] [Abstract][Full Text] [Related]
3. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
[TBL] [Abstract][Full Text] [Related]
4. Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells.
Tabellini G; Cappellini A; Tazzari PL; Falà F; Billi AM; Manzoli L; Cocco L; Martelli AM
J Cell Physiol; 2005 Feb; 202(2):623-34. PubMed ID: 15316930
[TBL] [Abstract][Full Text] [Related]
5. Serum bioactive lysophospholipids prevent TRAIL-induced apoptosis via PI3K/Akt-dependent cFLIP expression and Bad phosphorylation.
Kang YC; Kim KM; Lee KS; Namkoong S; Lee SJ; Han JA; Jeoung D; Ha KS; Kwon YG; Kim YM
Cell Death Differ; 2004 Dec; 11(12):1287-98. PubMed ID: 15297884
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
Ravi R; Bedi A
Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
[TBL] [Abstract][Full Text] [Related]
7. Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance.
Thakkar H; Chen X; Tyan F; Gim S; Robinson H; Lee C; Pandey SK; Nwokorie C; Onwudiwe N; Srivastava RK
J Biol Chem; 2001 Oct; 276(42):38361-9. PubMed ID: 11461904
[TBL] [Abstract][Full Text] [Related]
8. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors.
Aggarwal BB; Bhardwaj U; Takada Y
Vitam Horm; 2004; 67():453-83. PubMed ID: 15110190
[TBL] [Abstract][Full Text] [Related]
9. TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2.
Alladina SJ; Song JH; Davidge ST; Hao C; Easton AS
J Vasc Res; 2005; 42(4):337-47. PubMed ID: 15985761
[TBL] [Abstract][Full Text] [Related]
10. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells.
Kandasamy K; Srivastava RK
Cancer Res; 2002 Sep; 62(17):4929-37. PubMed ID: 12208743
[TBL] [Abstract][Full Text] [Related]
11. Akt protects mouse hepatocytes from TNF-alpha- and Fas-mediated apoptosis through NK-kappa B activation.
Hatano E; Brenner DA
Am J Physiol Gastrointest Liver Physiol; 2001 Dec; 281(6):G1357-68. PubMed ID: 11705740
[TBL] [Abstract][Full Text] [Related]
12. PI-3K/Akt and NF-kappaB/IkappaBalpha pathways are activated in Jurkat T cells in response to TRAIL treatment.
Zauli G; Sancilio S; Cataldi A; Sabatini N; Bosco D; Di Pietro R
J Cell Physiol; 2005 Mar; 202(3):900-11. PubMed ID: 15389633
[TBL] [Abstract][Full Text] [Related]
13. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Mitsiades CS; Mitsiades N; Poulaki V; Schlossman R; Akiyama M; Chauhan D; Hideshima T; Treon SP; Munshi NC; Richardson PG; Anderson KC
Oncogene; 2002 Aug; 21(37):5673-83. PubMed ID: 12173037
[TBL] [Abstract][Full Text] [Related]
14. Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP.
Rokhlin OW; Guseva NV; Tagiyev AF; Glover RA; Cohen MB
Prostate; 2002 Jun; 52(1):1-11. PubMed ID: 11992615
[TBL] [Abstract][Full Text] [Related]
15. cFLIPL inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappaB activation at the death-inducing signaling complex in human keratinocytes.
Wachter T; Sprick M; Hausmann D; Kerstan A; McPherson K; Stassi G; Bröcker EB; Walczak H; Leverkus M
J Biol Chem; 2004 Dec; 279(51):52824-34. PubMed ID: 15459191
[TBL] [Abstract][Full Text] [Related]
16. Selective targeting of the nuclear factor-kappaB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death.
Thomas RP; Farrow BJ; Kim S; May MJ; Hellmich MR; Evers BM
Surgery; 2002 Aug; 132(2):127-34. PubMed ID: 12219002
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
Zhang L; Fang B
Cancer Gene Ther; 2005 Mar; 12(3):228-37. PubMed ID: 15550937
[TBL] [Abstract][Full Text] [Related]
18. NF-kappa B does not modulate sensitivity of renal carcinoma cells to TNF alpha-related apoptosis-inducing ligand (TRAIL).
Pawlowski JE; Nesterov A; Scheinman RI; Johnson TR; Kraft AS
Anticancer Res; 2000; 20(6B):4243-55. PubMed ID: 11205254
[TBL] [Abstract][Full Text] [Related]
19. NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling.
Kreuz S; Siegmund D; Scheurich P; Wajant H
Mol Cell Biol; 2001 Jun; 21(12):3964-73. PubMed ID: 11359904
[TBL] [Abstract][Full Text] [Related]
20. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes.
Leverkus M; Neumann M; Mengling T; Rauch CT; Bröcker EB; Krammer PH; Walczak H
Cancer Res; 2000 Feb; 60(3):553-9. PubMed ID: 10676636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
